岸迈生物冲刺港交所：专注双特异性抗体，已达成超21亿美元授权合作

Core Viewpoint - Anmai Biotech Co., Ltd. is preparing for an IPO on the Hong Kong Stock Exchange, focusing on developing T-cell engagers for cancer and autoimmune diseases, with significant global partnerships and a strong clinical pipeline [1][2][5]. Group 1: Company Overview - Anmai Biotech was established in 2015 and is a clinical-stage biotechnology company specializing in T-cell engagers for various cancers and autoimmune diseases [2]. - The company has received investments from notable institutions including CITIC Capital, Decheng Capital, and others [6]. Group 2: Clinical Pipeline - Anmai Biotech's oncology pipeline includes three clinical-stage candidates: EMB-01 for colorectal cancer, EMB-06 for multiple myeloma, and EMB-07 for lymphoma and solid tumors [3][4]. - EMB-01 is the world's first EGFR/cMET bispecific antibody to enter Phase II trials for colorectal cancer, with a focus on metastatic colorectal cancer [4]. Group 3: Market Position and Partnerships - As of the end of 2023, Anmai Biotech has established multiple global licensing collaborations with a total transaction value exceeding $2.1 billion, ranking second globally in the T-cell engager field [5]. - The company aims to use the net proceeds from the IPO to fund ongoing and planned clinical trials for its core product EMB-01 and other pipeline assets [7].